Use of a Small Molecule CCR5 Inhibitor in Macaques to Treat Simian Immunodeficiency Virus Infection or Prevent Simian-Human Immunodeficiency Virus Infection

Journal of Experimental Medicine

Volumn 198, Issue 10, 2003, Pages 1551-1562

  Veazey, Ronald S ^a   Klasse, Per Johan ^b   Ketas, Thomas J ^b   Reeves, Jacqueline D ^c   Piatak Jr , Michael ^d   Kunstman, Kevin ^e   Kuhmann, Shawn E ^b   Marx, Preston A ^a   Lifson, Jeffrey D ^d   Dufour, Jason ^a   Mefford, Megan ^a   Pandrea, Ivona ^a   Wolinsky, Steven M ^e   Doms, Robert W ^c   DeMartino, Julie A ^f   Siciliano, Salvatore J ^f   Lyons, Kathy ^f   Springer, Martin S ^f   Moore, John P ^b  

^a TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d SAIC FREDERICK INC   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

AIDS; Antiretroviral therapy; Chemokine receptor; HIV; Microbicide

Indexed keywords

ANTIVIRUS AGENT; CHEMOKINE RECEPTOR CCR5; CMPD 167; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EXPERIMENTAL INFECTION; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SEXUAL TRANSMISSION; SIMIAN IMMUNODEFICIENCY VIRUS; SIMIAN IMMUNODEFICIENCY VIRUS INFECTION; VIREMIA; VIRUS INFECTION; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSMISSION;

ANIMALS; ANTI-RETROVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; MACACA MULATTA; PYRAZOLES; RECEPTORS, CCR5; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VALINE;

EID: 10744225125     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20031266     Document Type: Article

References (69)

1. Wyatt, R., and J. Sodroski. 1998. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science. 280:1884-1888.
2. Doms, R.W., and J.P. Moore. 2000. HIV-1 membrane fusion: targets of opportunity. J. Cell Biol. 151:F9-F14.
3. Berger, E.A., P.M. Murphy, and J.M. Farber. 1999. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17:657-700.
4. Doms, R.W. 2001. Chemokine receptors and HIV entry. AIDS. 15:S34-S35.
5. Dragic, T. 2001. An overview of the determinants of CCR5 and CXCR4 co-receptor function. J. Gen. Virol. 82:1807-1814.
6. Clapham, P.R., and A. McKnight. 2002. Cell surface receptors, virus entry and tropism of primate lentiviruses. J. Gen. Virol. 83:1809-1829.
7. Liu, R., W.A. Paxton, S. Choe, D. Ceredini, S.R. Martin, R. Horuk, M.E. MacDonald, H. Stuhlmann, R.A. Koup, and N.R. Landau. 1996. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell. 86:367-377.
8. Samson, M., F. Libert, B.J. Doranz, J. Rucker, C. Liesnard, C.M. Farber, S. Saragosti, C. Lapoumeroulie, J. Cognaux, C. Forceille, et al. 1996. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature. 382:722-725.
9. Dean, M., M. Carrington, C. Winkler, G.A. Huttley, M.W. Smith, R. Allikmets, J.J. Goedert, S.P. Buchbinder, E. Vittinghoff, E. Gomperts, et al. 1996. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science. 273:1856-1862. (published erratum appears in Science. 1996. 274:1069)
10. Dean, M., M. Carrington, C. Winkler, G.A. Huttley, M.W. Smith, R. Allikmets, J.J. Goedert, S.P. Buchbinder, E. Vittinghoff, E. Gomperts, et al. 1996. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science. 273:1856-1862. (published erratum appears in Science. 1996. 274:1069)
11. O'Brien, S.J., and J.P. Moore. 2000. The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS. Immunol. Rev. 177:99-111.
12. Moore, J.P., and M. Stevenson. 2000. New targets for inhibitors of HIV-1 replication. Nat. Rev. Mol. Cell Biol. 1:40-49.
13. Richman, D.D. 2001. HIV chemotherapy. Nature. 410:995-1001.
14. Baroudy, B. 2002. AIDS-14th International Conference (Part I), New Drugs, New Targets Symposium. 24.
15. Reynes, J., R. Rouzier, T. Kanouni, V. Baillat, B. Baroudy, A. Keung, C. Hogan, M. Markowitz, and M. Laughlin. 2002. SCH C: Safety and antiviral effects of a CCR5 receptor antagonist in HIV-1 infected subjects. 9th Conference on Retroviruses and Opportunistic Infections. 53.
16. Schwarz, M.K., and T.N. Wells. 2002. New therapeutics that modulate chemokine networks. Nat. Rev. Drug Disc. 1:347-358.
17. Kazmierski, W., N. Bifulco, H. Yang, L. Boone, F. DeAnda, C. Watson, and T. Kenakin. 2003. Recent progress in discovery of small-molecule CCR5 chemokine receptor ligands as HIV-1 inhibitors. Bioorg. Med. Chem. 11:2663-2676.
18. Kilby, J.M., and J.J. Eron. 2003. Novel therapies based on mechanisms of HIV-1 cell entry. N. Engl. J. Med. 348:2228-2238.
19. Lalezari, J.P., K. Henry, M. O'Hearn, J.S. Montaner, P.J. Piliero, B. Trottier, S. Walmsley, C. Cohen, D.R. Kuritzkes, J.J. Eron, Jr., et al. 2003. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N. Engl. J. Med. 348:2175-2185.
20. Lazzarin, A., B. Clotet, D. Cooper, J. Reynes, K. Arasteh, M. Nelson, C. Katlama, H.J. Stellbrink, J.F. Delfraissy, J. Lange, et al. 2003. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N. Engl. J. Med. 348:2186-2195.
21. Turpin, J.A. 2002. Considerations and development of topical microbicides to inhibit the sexual transmission of HIV. Expert Opin. Investig. Drugs. 11:1077-1097.
22. Stone, A. 2002. Microbicides: a new approach to preventing HIV and other sexually transmitted infections. Nat. Rev. Drug Discov. 1:977-985.
23. Shattock, R.A., and J.P. Moore. 2003. Inhibiting HIV-1 sexual transmission. Nat. Rev. Microbiol. 1:25-34.
24. Finke, P.E., B. Oates, L.C. Meurer, J.L. Loebach, K.A. Parker, J.J. Hale, C.L. Lynch, R.J. Budhu, A.L. Gentry, C.G. Caldwell, et al. 2002. The discovery of potent human CCR5 antagonists based on a cyclopentane scaffold. Inflammation Research Association 11th National Convention Proceedings. A56:S130.
25. Kumar, S., G.Y. Kwei, G.K. Pook, S.A. Iliff, Y. Wang, Q. Chen, R.B. Franklin, V. Didolkar, R.W. Wang, M. Yamazaki, et al. 2003. Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with Ritonavir in rats and monkeys. J. Pharm. Exp. Therapeutics. 304:1161-1171.
26. Veazey, R.S., R.J. Shattock, M. Pope, J.C. Kirijan, J. Jones, Q. Hu, T. Ketas, P.A. Marx, P.J. Klaase, D.R. Burton, and J.P. Moore. 2003. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV gp120. Nat. Med. 9:343-346.
27. Pal, R., B. Taylor, S. Foulke, R. Woodward, M. Merges, R. Praschunus, A. Gibson, and M. Reitz. 2003. Characterization of a simian human immunodeficiency virus encoding the envelope gene from the CCR5-tropic HIV-1 Ba-L. J. Acquir. Immune Defic. Syndr. 33:300-307.
28. Enose, Y., A. Miyake, E. Ido, and M. Hayami. 2003. Infection of a chimeric simian and human immunodeficiency virus with CCR5-specific HIV-1 envelope to rhesus macaques. J. Vet. Med. Sci. 65:283-286.
29. Edinger, A.L., T.L. Hoffman, M. Sharron, B. Lee, B. O'Dowd, and R.W. Doms. 1998. Use of GPR1, GPR15, and STPL33 as coreceptors by diverse human immunodeficiency virus type 1 and simian immunodeficiency virus envelope proteins. Virol. 249:367-378.
30. Zhang, Y., B. Lou, R.B. Lal, A. Gettie, P.A. Marx, and J.P. Moore. 2000. Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells. J. Virol. 74:6893-6910.
31. Harouse, J.M., A. Gettie, R.C. Tan, J. Blanchard, and C. Cheng-Mayer. 1999. Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. Science. 284:816-819.
32. Harouse, J.M., A. Gettie, T. Eshetu, R.C. Tan, R. Bohm, J. Blanchard, G. Baskin, and C. Cheng-Mayer. 2001. Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIV(SF162P3). J. Virol. 75:1990-1995.
33. Marx, P.A., A.I. Spira, A. Gettie, P.J. Dailey, R.S. Veazey, A.A. Lackner, C.J. Mahoney, C.J. Miller, L.E. Claypool, D.D. Ho, and NJ. Alexander. 1996. Progesterone implants enhance SIV vaginal transmission and early virus load. Nat. Med. 2:1084-1089.
34. Trichel, A.M., E.D. Roberts, L.A. Wilson, L.N. Martin, R.M. Ruprecht, and M. Murphey-Corb. 1997. SIV/DeltaB670 transmission across oral, colonic, and vaginal mucosae in the macaque. J. Med. Primatol. 26:3-10.
35. Reimann, K.A., J.T. Li, R. Veazey, M. Halloran, I.W. Park, G.B. Karlsson, J. Sodroski, and N.L. Letvin. 1996. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J. Virol. 70:6922-6928.
36. Trkola, A., S.E. Kuhmann, J.M. Strizki, E. Maxwell, T. Ketas, T. Morgan, P. Pugach, S. Xu, L. Wojcik, J. Tagat, et al. 2002. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc. Natl. Acad. Sci. USA. 99:395-400.
37. Veazey, R.S., B. Ling, I. Pandrea, H. McClure, A.A. Lackner, and P.A. Marx. 2003. Decreased CCR5 expression on CD4+ T cells of SIV-infected sooty mangabeys. AIDS Res. Hum. Retroviruses. 19:227-233.
38. Lifson, J.D., J.L. Rossio, M. Piatak, Jr., T. Parks, L. Li, R. Kiser, V. Coalter, B. Fisher, B.M. Flynn, S. Czajak, et al. 2001. Role of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment. J. Virol. 75:10187-10199.
39. Feinberg, M.B., J.M. McCune, F. Miedema, J.P. Moore, and H. Schuitemaker. 2002. HIV tropism and CD4+ T-cell depletion. Nat. Med. 8:537.
40. Ling, B., R.S. Veazey, A. Luckay, C. Penedo, K. Xu, J.D. Lifson, and P.A. Marx. 2002. SIV(mac) pathogenesis in rhesus macaques of Chinese and Indian origin compared with primary HIV infections in humans. AIDS. 16:1489-1496.
41. Bronson, R.T., M. O'Connell, N. Klepper-Kilgore, L.V. Chalifoux, and P. Sehgal. 1982. Fatal fasting syndrome of obese macaques. Lab. Anim. Sci. 32:187-192.
42. Moore, J.P., and R.W. Doms. 2003. The entry of entry inhibitors; a fusion of science and medicine. Proc. Natl. Acad. Sci. USA. 100:10598-10602.
43. Bonhoeffer, S., R.M. May, G.M. Shaw, and M.A. Nowak. 1997. Virus dynamics and drug therapy. Proc. Natl. Acad. Sci. USA. 94:6971-6976.
44. Perelson, A.S. 2002. Modelling viral and immune system dynamics. Nat. Rev. Immunol. 2:28-36.
45. Shen, A., M.C. Zink, J.L. Mankowski, K. Chadwick, J.B. Margolick, L.M. Carruth, M. Li, J.E. Clements, and R.F. Siliciano. 2003. Resting CD4+ T lymphocytes but not thymocytes provide a latent viral reservoir in a simian immunodeficiency virus-Macaca nemestrina model of human immunodeficiency virus type 1-infected patients on highly active antiretroviral therapy. J. Virol. 77:4938-4949.
46. Paxton, W.A., S.R. Martin, D. Tse, T.R. O'Brien, J. Skurnick, N.L. VanDevanter, N. Padian, J.F. Braun, D.P. Kotler, S.M. Wolinsky, and R.A. Koup. 1996. Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure. Nat. Med. 2:412-417.
47. Paxton, W.A., A.U. Neumann, S. Kang, L. Deutch, R.C. Brown, R.A. Koup, and S.M. Wolinsky. 2001. RANTES production from CD4+ lymphocytes correlates with host genotype and rates of human immunodeficiency virus type 1 disease progression. J. Infect. Dis. 183:1678-1681.
48. Reeves, J.D., S.A. Gallo, N. Ahmad, J.L. Miamidian, P.E. Harvey, M. Sharron, S. Pohlmann, J.N. Sfakianos, C.A. Derdeyn, R. Blumenthal, et al. 2002. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc. Natl. Acad. Sci. USA. 99:16249-16254.
49. Moore, J.P. 1997. Coreceptors: implications for HIV pathogenesis and therapy. Science. 276:51-52.
50. Wu, L., W.A. Paxton, N. Kassam, N. Ruffing, J.B. Rottman, N. Sullivan, H. Choe, J. Sodroski, W. Newman, R.A. Koup, and C.R. Mackay. 1997. CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J. Exp. Med. 185:1681-1691.
51. Cocchi, F., A.L. DeVico, R. Yarchoan, R. Redfield, F. Cleghorn, W.A. Blattner, A. Garzino-Demo, S. Colombini-Hatch, D. Margolis, and R.C. Gallo. 2000. Higher macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels from CD8+ T cells are associated with asymptomatic HIV-1 infection. Proc. Natl. Acad. Sci. USA. 97:13812-13817.
52. Lee, B., M. Sharron, L.J. Montaner, D. Weissman, and R.W. Doms. 1999. Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc. Natl. Acad. Sci. USA. 96:5215-5220.
53. Sabbe, R., G.R. Picchio, C. Pastore, O. Chaloin, O. Hartley, R. Offord, and D.E. Mosier. 2001. Donor- and ligand-dependent differences in C-C chemokine receptor 5 reexpression. J. Virol. 75:661-671.
54. Sharron, M., S. Pohlmann, K. Price, E. Lolis, M. Tsang, F. Kirchhoff, R.W. Doms, and B. Lee. 2000. Expression and coreceptor activity of STRL33/Bonzo on primary peripheral blood lymphocytes. Blood. 96:41-49.
55. Zhang, Y.J., T. Dragic, Y. Cao, L. Kostrikis, D.S. Kwon, D.R. Littman, V.N. KewalRamani, and J.P. Moore. 1998. Use of coreceptors other than CCR5 by non-syncytium-inducing adult and pediatric isolates of human immunodeficiency virus type 1 is rare in vitro. J. Virol. 72:9337-9344.
56. Zhang, Y.J., and J.P. Moore. 1999. Will multiple coreceptors need to be targeted by inhibitors of human immunodeficiency virus type 1 entry? J. Virol. 73:3443-3448.
57. Pohlmann, S., B. Lee, S. Meister, M. Krumbiegel, G. Leslie, R.W. Doms, and F. Kirchhoff. 2000. Simian immunodeficiency virus utilizes human and sooty mangabey but not rhesus macaque STRL33 for efficient entry. J. Virol. 74:5075-5082.
58. Davey, R.T., Jr., N. Bhat, C. Yoder, T.W. Chun, J.A. Metcalf, R. Dewar, V. Natarajan, R.A. Lempicki, J.W. Adelsberger, K.D. Miller, et al. 1999. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc. Natl. Acad. Sci. USA. 96:15109-15114.
59. Chun, T.W., R.T. Davey, Jr., M. Ostrowski, J. Shawn Justement, D. Engel, J.I. Mullins, and A.S. Fauci. 2000. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat. Med. 6:757-761.
60. Tremblay, C.L., F. Giguel, C. Kollmann, Y. Guan, T.C. Chou, B.M. Baroudy, and M.S. Hirsch. 2002. Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro. Antimicrob. Agents Chemother. 46:1336-1339.
61. Nagashima, K.A., D.A. Thompson, S.I. Rosenfield, P.J. Maddon, T. Dragic, and W.C. Olson. 2001. Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion. J. Infect. Dis. 183:1121-1125.
62. Shattock, R.J., G.E. Griffin, and G.I. Gorodeski. 2000. In vitro models of mucosal HIV transmission. Nat. Med. 6:607-608.
63. Greenhead, P., P. Hayes, P.S. Watts, K.G. Laing, G.E. Griffin, and R.J. Shattock. 2000. Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides. J. Virol. 74:5577-5586.
64. Frank, I., and M. Pope. 2002. The enigma of dendritic cell-immunodeficiency virus interplay. Curr. Mol. Med. 2:229-248.
65. Pope, M., and A.T. Haase. 2003. Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. Nat. Med. 9:847-852.
66. Kawamura, T., F.O. Gulden, M. Sugaya, D.T. McNamara, D.L. Borris, M.M. Lederman, J.M. Orenstein, P.A. Zimmerman, and A. Blauvelt. 2003. R5 HIV productively infects Langerhans cells, and infection levels are regulated by compound CCR5 polymorphisms. Proc. Natl. Acad. Sci. USA. 100:8401-8406.
67. Kwon, D.S., G. Gregorio, N. Bitton, W.A. Hendrickson, and D.R. Littman. 2002. DC-SIGN-mediated internalization of HIV is required for trans-enhancement of T cell infection. Immunity. 16:135-144.
68. Pohlmann, S., F. Baribaud, and R.W. Doms. 2001. DC-SIGN and DC-SIGNR: helping hands for HIV. Trends Immunol. 22:643-646.
69. Kawamura, T., S.S. Cohen, D.L. Borris, E.A. Aquilino, S. Glushakova, L.B. Margolis, J.M. Orenstein, R.E. Offord, A.R. Neurath, and A. Blauvelt. 2000. Candidate microbicides block HIV-1 infection of human immature Langerhans cells within epithelial tissue explants. J. Exp. Med. 192:1491-1500.